Introduction {#s1}
============

Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by protein truncating mutations in the *DMD* gene leading to dystrophin absence.[@R1] Differences in disease progression, the reasons for which are largely unknown, have been described in the past.[@R2] [@R3] It has been hypothesised that variation in the inflammatory response to muscle damage could be responsible for the differences among patients. Evidence for this hypothesis was recently described in two papers reporting a relationship between the single nucleotide polymorphism (SNP) rs28357094 in the *SPP1* gene and disease severity.[@R4] [@R5] The same SNP was later reported to influence muscle size in healthy females.[@R6] It has also been shown that osteopontin, the *SPP1* gene product, has pro-inflammatory effects and worsens the muscle phenotype of mice lacking dystrophin.[@R7]

Recently an haplotype composed of four non-synonymous SNPs in the latent transforming growth factor-β (TGF-β) binding protein 4 (*LTBP4*) gene has also been associated with delayed disease progression in patients with DMD.[@R8] The SNPs involved are rs2303729, rs1131620, rs1051303 and rs10880 coding for V194I, T787A, T820A and T1141M amino acids, respectively (SNPs mapped to Uniprot isoform Q8N2S1-1, also known as LTBP-4L). Flanigan and co-authors described the IAAM haplotype to be associated with prolonged ambulation in patients with DMD. It has been postulated that the LTBP4 protein carrying IAAM amino acids is able to reduce TGF-β signalling via altered TGF-β binding or release; this would benefit patients' muscle regeneration capacity and reduce muscle fibrosis. These results are in line with previous findings in a mouse model for γ-sarcoglycanopathy where *LTBP4* was reported as a modifier for muscular dystrophy.[@R9]

In the current study, we aimed to validate whether the *SPP1* rs28357094 SNP and *LTBP4* IAAM haplotypes modulate disease progression in a large multicentre cohort composed of five independent subcohorts from four different countries. Two cohorts were from the UK (Newcastle and London), one from the Netherlands (Leiden), one from France (Montpellier) and one from Italy (Ferrara). The approach took advantage of the resources and harmonised standard operating procedures developed in the FP7-funded BIO-NMD consortium.

Methods {#s2}
=======

Patients {#s2a}
--------

Patients with a mutation in the *DMD* gene and absence of dystrophin in the skeletal muscle were included from neuromuscular databases in Leiden (the Netherlands), Ferrara (Italy), Montpellier (France), Newcastle and London (UK). The genetic tests used to diagnose the patients were performed by each laboratory independently, using standardised assays as per international guidelines.[@R10] Patients were selected giving priority to non-ambulant patients, thus enabling a more complete description of the disease course and reduce censoring during the analysis. Patients' selection was also based on comparable historical periods to reduce the variation that could be introduced by different standards of care; the mean year of birth per cohort is reported in [table 1](#JNNP2014308409TB1){ref-type="table"}. Age at follow-up and age at which ambulation was lost (when applicable) were documented. Information about corticosteroid use was noted, as it is known that steroid treatment is able to slow down disease progression.[@R11] [@R12] We considered corticosteroid-treated patients, the ones who started treatment at least 2.5 years prior to wheelchair dependence and continued treatment for at least 1 year. These cut-off points were chosen to ensure timing and duration of steroid treatment which could indeed impact age of wheelchair dependence. The study was approved by the local Research Ethics Committee prior to its start. Written informed consent for anonymised use of patients' data for scientific purposes was obtained.

###### 

Characteristics of the cohorts for the analysis of single nucleotide polymorphisms (SNPs) in *SPP1* and *LTBP4* genes

                                                                 Leiden   Ferrara   Montpellier   Newcastle   London
  -------------------------------------------------------------- -------- --------- ------------- ----------- --------
  *SPP1*                                                                                                      
  Patients                                                       65       43        107           68          53
  Wheelchair dependent                                           47       43        107           45          46
  Mean birth year                                                1993     1989      1989          1995        1995
  Steroid use                                                                                                 
   Yes                                                           27       13        7             34          21
   No                                                            38       30        100           34          32
  Mean age of ambulation loss in non-ambulant patients (years)                                                
   Overall                                                       9.6      10.1      9.5           10.5        10.8
   Steroid treated                                               10.5     11.5      9.8           12.1        11.6
   Non-steroid treated                                           9.2      9.4       9.5           9.7         10.3
  SNP frequencies                                                                                             
   TT                                                            52.3     65.1      61.7          64.7        62.3
   GT/GG                                                         47.7     34.9      38.3          35.3        37.7
  *LTBP4*                                                                                                     
  Patients                                                       63       43        38            69          52
  Wheelchair dependent                                           46       43        38            46          45
  Mean birth year                                                1993     1989      1987          1995        1995
  Steroid use                                                                                                 
   Yes                                                           27       13        2             34          20
   No                                                            36       30        36            35          32
  Mean age of ambulation loss in non-ambulant patients (years)                                                
   Overall                                                       9.6      10.1      9.5           10.6        10.8
   Steroid treated                                               10.5     11.5      8.6           12.1        11.7
   Non-steroid treated                                           9.1      9.4       9.6           9.8         10.3
  Haplotype frequencies                                                                                       
   VTTT                                                          52.0     49.3      51.2          47.6        41.9
   IAAM                                                          30.6     28.8      29.8          37.4        47.0
   Other                                                         17.4     21.9      19.0          15.0        11.1

*SPP1* genotyping {#s2b}
-----------------

DNA samples from Newcastle, Leiden, London and Ferrara were amplified by real-time PCR followed by melting curve analysis using the LightScanner (Idaho Technology Inc, Salt Lake City, Utah, USA; see online supplementary figure S1A). PCR reactions were performed in a final volume of 10 µL containing 20 ng of genomic DNA, 1X PCR Buffer (Roche, Woerden, the Netherlands), 1X LCGreen Plus (Idaho Technology Inc), 200 µM dNTPs (Life Technologies, Bleiswijk, the Netherlands), 2 mM MgCl~2~ (Roche), 0.3 μM forward and reverse primer (Eurogentec, Maastricht, the Netherlands; see online supplementary table S1), 0.4 μM low calibrators (Eurogentec; see online supplementary table S1) and 0.5 U FastStart PCR Taq DNA Polymerase (Roche). The thermal profile was as follows: 10 min at 95°C, then 40 cycles of 20 s at 95°C, 30 s at 60°C, 40 s at 72°C and a final step of 5 min at 72°C. PCR products were denatured at 95°C for 1 min, rapidly cooled down to room temperature and melted from 50°C to 98°C at a melt ramp rate of 2°C/s. The fluorescence was measured in real-time with the LightScanner software (Idaho Technology Inc). Low calibrators were used as internal controls to improve genotyping by melting.[@R13] Three samples with a known genotype for rs28357094 (GG, TT and GT), determined by Sanger sequencing, were used as internal quality controls. This procedure was developed and performed at the Leiden University Medical Center (LUMC) in Leiden for all samples from Newcastle, Leiden, London and Ferrara.

DNA samples from Montpellier were genotyped by Sanger sequencing in Montpellier (see online supplementary figure S1B). The sequence of the primers used for amplification is indicated in online supplementary table S1.

*LTBP4* genotyping {#s2c}
------------------

To assay SNPs rs2303729, rs1131620, rs1051303 and rs10880, we used the Sequenom MassARRAY platform (Sequenom Inc, San Diego, California, USA) according to manufacturer\'s protocols, except for the PCR cycling protocol, which was performed as a step-down protocol (see online supplementary methods). Multiplex genotyping assays were designed using Sequenom MassARRAY Assay Design Suite, V.1.0 (Sequenom Inc). After a step-down PCR, a primer extension reaction was performed to introduce mass differences between alleles. Primer sequences are indicated in online supplementary table S2. The product was spotted onto a target chip with 384 patches containing matrix. Mass differences were detected using the MassARRAY Compact System (Bruker, Wormer, the Netherlands) by matrix-assisted laser desorption\\ionisation time-of-flight mass spectrometry (MALDI-TOF). Data were acquired in real time with the MassARRAY RT software (Sequenom Inc) and genotypes were assigned using MassARRAY Typer 4.0.22 software (Sequenom Inc). Quality control was performed by duplicating 38 samples within and across plates and by the incorporation of control DNA as positive control and water as negative control.

Statistical analysis {#s2d}
--------------------

SNPs were tested for Hardy-Weinberg equilibrium using a goodness-of-fit test. Statistical analysis of the *SPP1* SNP was performed employing a multivariate Cox regression analysis using steroid use, cohort and genotype as covariates. A second regression analysis was performed including the same covariates as in the first model but also including an interaction term between corticosteroid treatment and genotype. Patients who were still ambulant at the time of analysis were censored. We used a dominant model for the minor G-allele as previously described.[@R4] [@R5] *LTBP4* haplotypes were reconstructed using the haplo.stats package in R. Haplotypes with a frequency below 10% were grouped together to form a single category. For two individuals haplotype reconstruction was ambiguous and the most likely configuration was chosen for these individuals. Cox regression analysis was performed using steroid use, cohort and the *LTBP4* haplotype as covariates. Patients who were still ambulant at the time of analysis were censored. Data were analysed using the additive as well as recessive model. In the additive model diplotypes with one copy of the IAAM haplotype were considered intermediate, while IAAM/IAAM diplotypes were considered the extreme. Haplotypes with a frequency below 10% were grouped together for the analysis with the additive model; this enabled us to work with three haplotypes groups: VTTT, IAAM and other ([table 1](#JNNP2014308409TB1){ref-type="table"}). The analysis with the additive model was performed using VTTT as well as other as reference haplotypes. The analysis with the recessive model was performed dividing patients into two groups: IAAM/IAAM diplotypes and other/other diplotypes. Age at wheelchair dependence was used as dependent variable in all analyses. This parameter was chosen as it is a robust measurement of disease severity, and data about loss of ambulation were available for all cohorts. Statistical analysis was performed and p values below 0.05 were considered significant. Analyses were performed using IBM SPSS software and R V.2.15.3.

Results {#s3}
=======

SPP1 {#s3a}
----

The *SPP1* SNP rs28357094 was genotyped in 336 patients with DMD (see online supplementary figures S1A,B). Two hundred and eighty-eight patients were wheelchair dependent (85.7%), 43 patients (12.8%) were censored, among whom 27 carried the TT genotype, and 16 carried the GT/GG genotype. Five cases (4 TT and 1 GT/GG) were dropped (1.5%) since they were censored before the earliest event. The steroid-treated group consisted of 102 patients (30.4%; [table 1](#JNNP2014308409TB1){ref-type="table"}). Corticosteroid-treated patients lost ambulation later compared to non-treated patients (11.9 vs 9.6 years; p\<0.001). There was no significant deviation from the Hardy Weinberg equilibrium for the studied SNP. There was no significant effect of the *SPP1* genotype on the age of ambulation loss (p=0.73; [table 2](#JNNP2014308409TB2){ref-type="table"} and [figure 1](#JNNP2014308409F1){ref-type="fig"}A, B), and no significant interaction between genotype and corticosteroid treatment (p=0.44). A significant effect of cohort on age at wheelchair dependence was observed. Patients from Newcastle and London were significantly associated with a delayed age at ambulation loss compared to patients belonging to the other cohorts ([table 2](#JNNP2014308409TB2){ref-type="table"}).

###### 

Analysis of the effect of steroid use, cohort and genotype on age at wheelchair dependence

                      HR\*   p Value
  ------------------- ------ ---------
  *SPP1*†                    
  Steroid use         0.38   \<0.001
  SPP1 SNP                   
   TT                 1.04   0.73
   GT/GG              1‡     --
  Cohort                     
   London             1.12   0.60
   Ferrara            1.72   0.01
   Montpellier        1.82   0.002
   Leiden             1.8    0.006
   Newcastle          1‡     --
  *LTBP4*†                   
  Additive model             
   Steroid use        0.31   \<0.001
  LTBP4 haplotype            
   IAAM               0.8    0.046
   VTTT               1‡     --
   other              1.16   0.29
  Cohort                     
   London             1.16   0.47
   Ferrara            1.62   0.03
   Montpellier        1.07   0.79
   Leiden             1.83   0.005
   Newcastle          1‡     --
  Recessive model            
   Steroid use        0.31   \<0.001
  LTBP4 diplotypes           
   IAAM/IAAM          1‡     --
   other diplotypes   1.3    0.01
  Cohort                     
   London             1.18   0.44
   Ferrara            1.69   0.02
   Montpellier        1.08   0.75
   Leiden             1.88   0.003
   Newcastle          1‡     --

*\**HR above 1 point to an earlier loss of ambulation compared to the reference, while HRs below 1 point to a later loss of ambulation compared to the reference.

**†**The reported values were obtained using a dominant model for the *SPP1* SNP and additive and recessive models for the *LTBP4* haplotype.

‡These conditions were used as reference, therefore their HRs are set at 1.

SNP, single nucleotide polymorphism.

![Survival plots showing the effect of single nucleotide polymorphism (SNP) rs28357094 (*SPP1*) for 336 patients with Duchenne muscular dystrophy (DMD). Survival plots for corticosteroid-untreated (A) and corticosteroid-treated (B) patients with DMD. The two survival lines represent patients stratified according to their *SPP1* SNP genotype (blue=TT, green=GT/GG). Censored patients are indicated by a cross on the lines.](jnnp-2014-308409f01){#JNNP2014308409F1}

LTBP4 {#s3b}
-----

We genotyped SNPs rs2303729, rs1131620, rs1051303 and rs10880 in 270 patients (for an example of rs10880 see online supplementary figure S2). The number of patients included in this part of the study is lower compared to the *SPP1* part due to a different technical set-up. Four samples failed and were excluded; another was excluded since the genotyping performed in duplicate was discordant; the other 37 patients in whom genotyping was performed in duplicate were all consistent. For two patients only three SNPs were genotyped and the fourth SNP was imputed based on the other three SNPs. The final number of patients considered for the analysis was 265. Two hundred and eighteen patients were wheelchair dependent (82.3%) and 47 patients (17.7%) were censored. The steroid group consisted of 96 patients (36.2%). There was no significant deviation from the Hardy Weinberg equilibrium for the studied SNPs. As shown by the study of Flanigan *et al*,[@R8] there was a strong linkage disequilibrium within the *LTBP4* locus, causing all four SNPs to be usually inherited together. The frequencies of the reconstructed haplotypes are shown in online supplementary table S3 and were in concordance with those published. [Table 1](#JNNP2014308409TB1){ref-type="table"} shows haplotype frequencies per cohort, highlighting how the IAAM haplotype was more frequent in the UK cohorts compared to the other cohorts. Corticosteroid treatment had a significant protective role (p\<0.001). The IAAM haplotype was associated with a significant delay in ambulation loss compared to the VTTT haplotype (p=0.046; [table 2](#JNNP2014308409TB2){ref-type="table"}) and to the other haplotypes (p=0.01; see online supplementary table S4) using the additive model. The additive effect of the IAAM haplotype is visible in [figure 2](#JNNP2014308409F2){ref-type="fig"}A, B for corticosteroid naïve and also for corticosteroid-treated patients. The effect of the IAAM haplotype was confirmed using the recessive model (p=0.01; [table 2](#JNNP2014308409TB2){ref-type="table"} and [figure 2](#JNNP2014308409F2){ref-type="fig"}C). Differences in age of ambulation loss were also identified among cohorts; patients from Newcastle, London and Montpellier were significantly associated with delayed ambulation loss compared to patients from Ferrara and Leiden ([table 2](#JNNP2014308409TB2){ref-type="table"}).

![Survival plots showing the effect of the IAAM haplotype (*LTBP4*) in 265 patients with Duchenne muscular dystrophy. Survival plots showing the additive effect of the IAAM haplotype in steroid naïve (A) and corticosteroid-treated (B) patients. (C) Comparison of individuals homozygous for the IAAM haplotype with individuals carrying other diplotypes separated for corticosteroid-treated and corticosteroid-untreated patients.](jnnp-2014-308409f02){#JNNP2014308409F2}

Discussion {#s4}
==========

DMD is the most common muscular dystrophy and is characterised by progressive muscle degeneration. Disease course varies among patients with most of the patients losing ambulation between 6 and 12 years of age. The reason behind the differences in disease progression is so far not clear. However, genetic modifiers in the *SPP1* and *LTBP4* loci have been proposed to contribute to the observed differences. Pegoraro *et al* reported evidence connecting SNP rs28357094, lying upstream of the *SPP1* gene promoter on chromosome 4, to age of wheelchair dependence. The authors showed that the TT genotype was associated with delayed disease progression in a study of 262 patients derived from two independent cohorts (106 patients from Italy and 156 patients from the USA).[@R5] Later on the same group published a second report in which patients participated in a 12- month longitudinal study where the 6 min walk test and the North Start Ambulatory Assessment were used as functional outcome measure; the authors were able to show that patients with the TT genotype progress slower compared to the other group.[@R4] We genotyped SNP rs28357094 in 336 patients from five independent European cohorts and were unable to replicate the published association between the SNP and age of ambulation loss. The association was also not significant when the interaction between corticosteroid treatment and genotype was included in the model. The lack of a clear association between this SNP and disease progression is in accordance with a recent publication from Flanigan *et al*,[@R8] who studied a US cohort composed of 254 non-ambulatory patients with DMD. In this study, the authors went further and presented evidence of a new genetic modifier composed of four SNPs located in the *LTBP4* locus. In line with the scope of this paper to replicate known genetic associations in patients with DMD, we also genotyped these 4 SNPs in 265 patients with DMD. Interestingly, we identified a significant association between the *LTBP4* haplotype and disease progression. As in the study by Flanigan *et al*, prolonged ambulation was associated with the IAAM haplotype, which is related to decreased TGF-β signalling. TGF-β is known to inhibit differentiation of satellite cells and increase fibrosis in muscle tissue.[@R14] Several studies have shown that inhibition of TGF-β function decreases the presence of fibrosis and increases muscle strength in *mdx* mice.[@R14] Reduced TGF-β signalling, as with the IAAM haplotype, could therefore slow-down disease progression in patients with DMD. As expected, in the *SPP1* and *LTBP4* analyses we observed a strong effect of steroid treatment in delaying disease progression (p\<0.001).[@R11] [@R12] We also observed a significant cohort effect with patients from the UK and France performing better compared to the other cohorts. This may be due to differences in the corticosteroid treatment regimen, to differences in the standards of care, given that the mean age of birth is different among the cohorts and that standards of care improve rapidly, or to differences in the definition of wheelchair dependence among the participating centres. In our study, the definition of ambulation loss was homogeneous within each centre, but it was not standardised among centres. It is therefore possible that part of the significant differences observed among the cohorts is due to different definitions of wheelchair dependence. This can be considered a limit of our study and a general limit in multicentre DMD studies where a significant number of patients is included to have sufficient statistical power. A limitation of our approach in replicating the published associations is constituted by the differences in percentage of corticosteroid-treated patients, which are lower compared to the published studies (54% in the study by Pegoraro *et al*, and 57% in the study by Flanigan *et al*) and which also greatly vary among the considered clinical centres ([table 1](#JNNP2014308409TB1){ref-type="table"}). However, differences in the definition of steroid users may partly account for the differences in these percentages as our definition is more conservative compared to the one of Flanigan *et al*. Another limitation of our study is the use of age at loss of ambulation as the sole measure for disease severity. Although this is one of the most important disease milestones, it is not sensitive to small effects. Indeed disease modifiers with a small effect could therefore be overlooked. Future studies should ideally include data about more sensitive measures, such as differences in motor function measures.

In conclusion, in the present study we confirm the disease modifying effect of the IAAM haplotype of the *LTBP4* gene, but could not replicate the previously described association between SNP rs28357094 in the *SPP1* gene and disease severity in patients with DMD. Future trials in DMD should consider the *LTBP4* haplotype before stratification, as it might confound the clinical trial results. This study underlines the possibilities and limitations of genetic association studies in rare diseases with inherently small cohort sizes.
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